Table 2.
Baseline concentrations of plasma markers of inflammation in patients with T2D according to outcome during 8–12 years of follow-up
| Baseline Plasma Marker | Outcome | P Valuea | ||||
|---|---|---|---|---|---|---|
| Alive (n=267) | ESRD (n=59) | Deceased (n=84) | Alive Compared with ESRD | Alive Compared with Deceased | ESRD Compared with Deceased | |
| ICAM-1 (ng/ml) | 171 (141, 197) | 184 (159, 233) | 181 (147, 229) | 1.00 | 1.00 | 1.00 |
| VCAM-1 (ng/ml) | 438 (358, 542) | 519 (451, 652) | 481 (424, 572) | 0.33 | 1.00 | 1.00 |
| PAI-1 (ng/ml) | 15.6 (11.0, 24.3) | 15.2 (9.0, 24.5) | 16.6 (11.8, 21.1) | 0.99 | 1.00 | 1.00 |
| IL-6 (pg/ml) | 1.6 (1.0, 2.3) | 2.3 (1.7, 3.6) | 2.3 (1.3, 3.4) | 1.00 | 0.05 | 1.00 |
| CRP (mg/L) | 3.0 (1.2, 6.5) | 4.8 (1.9, 7.8) | 4.2 (1.5, 7.7) | 1.00 | 1.00 | 1.00 |
| Free TNFα (pg/ml) | 3.9 (2.8, 5.5) | 8.3 (5.2, 11.1) | 4.9 (3.3, 7.6) | 0.002 | 1.00 | 0.83 |
| Total TNFα (pg/ml) | 10.3 (7.1, 14.4) | 23.0 (17.5, 29.4) | 14.1 (9.3, 21.3) | 0.02 | 1.00 | 0.35 |
| TNFR1 (pg/ml) | 1184 (1005, 1446) | 2424 (2137, 3704) | 1588 (1174, 2066) | <10−12 | 0.01 | <10−5 |
| TNFR2 (pg/ml) | 2273 (1898, 2708) | 4745 (3735, 7018) | 2969 (2225, 3841) | <10−11 | 0.02 | <10−4 |
Data are median (25th, 75th percentiles).
a
Adjusted for significant covariates in Table 1 (age, systolic BP, AER, eGFR, insulin treatment, and renoprotective treatment) and Bonferroni corrected for the number of markers and groups compared (n=3×9).